The chief complaint of dyspnea is common in patients presenting to the emergency department (ED). 5 Dyspnea can result from a variety of underlying conditions predominantly of cardiac or pulmonary origin, including acutely decompensated heart failure (ADHF), acute coronary syndrome (ACS), pulmonary embolism (PE), community-acquired pneumonia, and chronic obstructive pulmonary disease (COPD). The short-and longer-term mortality risk associated with each condition varies considerably and may be difficult to assess. Although clinical risk stratification models have been developed for several conditions that lead to dyspnea (1) (2) (3) (4) (5) , these models often lack important variables such as biomarkers, the use of which has recently been suggested for improved risk assessment (6 -11 ) . Furthermore, these models have defined risk in a particular disease/condition, but in a substantial number of patients these conditions coexist at presentation to an ED, a situation that results in complex risk prediction (12) (13) (14) (15) . Lastly, although risk models have been proposed for ED-based use, their longer-term value remains unclear.
In several previous analyses, using data from a clinical study of acute dyspnea in the ED setting (16 ), we examined several biochemical predictors of risk for death. In each of these analyses, however, the time horizon for follow-up was only 1 year (8 ) . Furthermore, during the follow-up period we accrued a large amount of data regarding several conventional and novel biomarkers. Because we have completed 4 years of follow-up for the participants in this trial, we compared all available biomarker results with respect to their ability to predict longer-term risk after patient presentation. To do so, we evaluated clinical and biochemical predictors of mortality at 4 years in these individuals. To validate these findings, we examined the consistency of risk prediction from our study in a dif-ferent population of dyspneic patients from a study performed in Linz, Austria (17 ) . Our hypothesis was that biomarkers, including conventional as well as more novel markers, would supplement clinical information for predicting risk among patients with acute dyspnea.
Methods
The institutional review board approved all study procedures, and all subjects gave informed consent.
THE PRIDE STUDY: DERIVATION COHORT
The design and results of the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study were previously reported (16 ) . Briefly, 599 dyspneic patients treated in an urban ED were enrolled in a study for the purpose of validating the value of aminoterminal pro-B-type natriuretic peptide (NT-proBNP) for diagnosis of ADHF in this setting. Study physicians (blinded to the results of NT-proBNP testing) assigned a final diagnosis for each patient. Of the 599 patients in the study, 209 (35%) were judged to have ADHF, whereas 390 (65%) had a diagnosis other than ADHF. Of those who did not have ADHF, 150 had exacerbations of COPD, 64 had pneumonia, 31 had ACS, 19 had acute PE, and 10 had acute bronchitis. In the additional 116 participants, various other diagnoses causing dyspnea were recorded, including anxiety attacks, allergic reactions, and ascites.
PRESENT STUDY
For the present study, we ascertained follow-up data on the 599 patients from the original PRIDE cohort by reviewing electronic medical records, the Social Security Death Index, and local obituary listings. Follow-up was complete in 99.7% of the PRIDE study participants.
BIOMARKER MEASUREMENTS
We examined a wide array of biomarkers in this analysis. These included the cardiac-specific biomarkers NT-proBNP [ In each study participant, hemoglobin, red cell distribution width, white blood cell count, sodium, blood urea nitrogen, creatinine, and estimated glomerular filtration rate (23 ) were measured.
STATISTICAL METHODS
Normally distributed demographic, clinical, and laboratory variables were generally described by use of means and SDs, and variables with asymmetric distributions were described with medians and interquartile ranges and log transformed for analyses. We performed comparisons of baseline clinical and laboratory characteristics by using Kruskal-Wallis testing.
SELECTION OF PREDICTORS FOR 4-YEAR MORTALITY
A total of 55 variables were tested in this analysis: these included variables from history, physical examination, and laboratory testing. Tobacco use was considered in the categories of never smoker, previous smoker, or active smoker. We performed risk-factor selection in a stepwise regression approach on the basis of minimization of a likelihood measure known as the Bayesian information criterion (BIC), which is similar to the approach used in devising the Reynolds risk scores for men and women (24, 25 ) . The BIC penalizes the log likelihood of a model by a factor related to the number of predictor variables in the model. Covariates were assessed in sequential models (adding 1 covariate at a time) with the goal of fitting a final parsimonious model for all dyspneic patients. The first variable for inclusion in the model (NT-proBNP) was selected on the basis of its univariate association with the outcome and minimization of the BIC. This covariate was then forced into the next model, and the covariate that minimized the BIC for these 2-covariate models was selected and forced into subsequent models. This process was repeated until there was no more improvement in the BIC. The model was then considered to be complete, and as parsimonious as possible. We assessed overall model fit by using the Akaike information criterion, likelihood ratio 2 , 2 P value, goodness-of-fit test, Harrell C statistic (for the Cox model used to examine time-to-event over a 4-year follow-up period), and area under the ROC curves (from a logistic regression model that used 4-year survival as the dependent variable and contained the identical set of covariates). To allow comparison of models with sequential addition of covariates, we performed all analyses in the derivation set on the same 517 patients (of whom 184 had ADHF and 171 died by the end of the 4-year follow-up period) with complete information on all covariates. To derive the final coefficients from the Cox model, we used data from all 561 patients for whom we had com-plete values for the final covariates selected to be in the model to estimate hazards for 4-year all-cause mortality. Hazard ratios (HRs) with 95% CIs were calculated.
PRIDE RISK MODEL FOR 4-YEAR MORTALITY
After derivation of the final parsimonious models for prediction of 4-year mortality, we developed a risk model by multiplying the ␤-coefficient by the covariate value and summing these to generate a point score for each individual patient. We then stratified patients by quintile of risk model and used Cox models to estimate HRs and Kaplan-Meier analysis to examine unadjusted survival.
The performance of the risk model was then externally validated in a well-described patient population from Linz, Austria (17 ) . In this prospective observational cohort study of 251 acutely dyspneic patients (mean age 70 years) presenting to the ED setting, comparable clinical and biochemical variables were available for analysis. Follow-up was complete in 100% of participants from Linz; by 4 years there were 128 deaths (51%). HR and unadjusted 4-year mortality rates were estimated by using the same cutpoints that defined the risk quintiles in the PRIDE cohort. Similarly, we plotted Kaplan-Meier cumulative incidence curves for the Linz patients for 4-year mortality with risk quintiles defined using the same cutpoints as in the PRIDE cohort.
We performed all analyses using Stata/MP version 10.1 for Windows (StataCorp). Proportional hazards assumptions were checked and found to be appropriate. A P value of Ͻ0.05 was defined as statistically significant.
Results

PATIENT CHARACTERISTICS
The baseline characteristics of the PRIDE (16 ) and Linz (17 ) cohorts have been previously published. Baseline clinical and laboratory characteristics of patients, including patient data presented as a function the occurrence of death by the end of the 4-year follow-up period, are detailed in Table 1 . Of the patients in the fully evaluable cohort (n ϭ 517), there were no significant differences when these patients were compared to the group as a whole. At the end of the 4-year follow-up period, death had occurred in 171 (33%) of 517 patients in the derivation group and in 183 (33%) of 561 patients in the group for which we had complete information on the covariates used for the final Cox model.
PREDICTORS OF MORTALITY AT 4 YEARS
The significant covariates that we assessed for their usefulness in the prediction of 4-year mortality for the entire cohort, in the order of selection (by sequential minimization of the BIC), were: NT-proBNP, sST2, age, hemoglobin, prevalent spironolactone use, and tobacco use (Table 2 ). Over and above the variables selected by use of the BIC, no additional prognostic information was contributed by left ventricular ejection fraction, diagnosis of ADHF, or measures of renal function. Candidate variables for prediction of death were then entered into a Cox proportional hazards analyses; as detailed in Table 3 , the statistical importance of each selected variable was verified. The method used to calculate the PRIDE risk score from the raw variables is shown in Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol56/issue12.
RISK SCORE PERFORMANCE AND VALIDATION
We developed risk prediction models including relevant variables. Given that several factors were inversely associated with survival, scores ranged from Ϫ61.1 to 144.7 (see online Supplemental Table 2) , with a mean score of Ϫ16.4 in the lowest quintile (referent). The performance of the risk model for prediction of death by 4 years is depicted by quintiles (see online Supplemental Tables 3 and 4) .
ROC curve analysis of the accuracy of the scores to discriminate the outcome of death by 4 years in the derivation cohort produced an area under the curve of 0.84 (P Ͻ 0.001) in the entire derived dyspneic cohort. As illustrated in online Supplemental Fig. 1 , a continuous increase in 4-year mortality was observed with increasing score quintile. The continuous nature of the score with respect to risk prediction is illustrated by the HR and 95% CI for each quintile ( Table 4) .
As demonstrated, a crude 4-year mortality rate of more than 75% was seen in the highest quintile (Q5) compared with a mortality rate of under 5% among those in the lowest quintile (Q1). The risk associated with being in higher quintiles appeared early, was well predicted by the risk model, and was sustained out to 4 years from follow-up (Fig. 1) .
In the validation cohort, the range of PRIDE risk scores varied from Ϫ39.1 to 139.0. The mean score in the referent group (lowest quintile) was Ϫ13.9. The area under the curve observed for the risk model was 0.76 (P Ͻ 0.001). In a similar fashion to the derivation cohort, the observed mortality rates in the validation cohort increased with rising quintile score, with the highest 4-year mortality rates among those in Q5, and considerably lower risk in Q1 (see online Supplemental  Fig. 2 ).
Discussion
In our cohort of acutely dyspneic patients, we observed that in addition to conventional risk factors such as advancing age and tobacco use, biomarkers including NT-proBNP, sST2, and hemoglobin significantly added to the ability to predict mortality as far as 4 years from presentation, whereas many other biomarkers were not selected to remain in the final model. We validated this model externally by applying the same risk model identified in PRIDE to a separate cohort of dyspneic patients with a heterogenous baseline risk; our findings remained strong, additionally confirming the primary hypothesis of our work, namely the importance of biomarkers for the thorough evaluation of the dyspneic patient. Given the dramatic increase in the number of biomarkers currently available or in development, the most parsimonious approach to the optimal application of such markers would be welcome. A major strength of our analysis includes the use of rigorous statistical methods, which narrows a wide field of candidates to a select few biomarkers that seem promising for use, including those recently established (NTproBNP), those that are emerging (sST2), and those widely in use (hemoglobin). This approach allows for justification of additional, more focused analyses of each of these markers relative to opportunities for therapeutic interventions based on their elevation. The methods used in this analysis avoided inclusion of variables that provided redundant information, and provided the most parsimonious yet most powerful model possible. Our methods mirror those used in development of widely published risk scores, such as the Reynolds risk scores for men and women (24, 25 ) .
The improvement of risk prediction in this setting is important: patients with acute dyspnea have an extremely wide range of risk at presentation, and their risk may be extraordinarily challenging to assess at first contact. The findings that both NT-proBNP and sST2 were selected by the BIC as more important predictors than age, and that the presenting diagnosis of ADHF was not a predictor of death in the presence of other variables are particularly noteworthy, given the importance of age and clinical diagnosis as prognostic markers. These finding not withstanding, the unifying concept of our analysis is that biomarkers add important information to clinical information among patients with acute dyspnea.
Among acutely dyspneic patients, we found NTproBNP to be the biomarker selected first in our modeling strategy by the BIC, indicating its strong association with 4-year mortality. Our results confirm previous findings of usefulness of NT-proBNP for 1-year mortality (8 ) but extend these findings consid- Table 4 . Performance of PRIDE risk score in derivation (PRIDE) and validation (Linz) cohorts, using the same cutpoints to define quintiles. erably, because our previous analysis lacked many of the biochemical variables examined in the present analysis and did not compare these biomarkers in as rigorous a fashion as we have in the present analysis. When NT-proBNP concentrations are increased, the usefulness of this biomarker for long-term risk prediction seems to extend to both HF-related and non-HFrelated dyspnea. In this context higher NT-proBNP concentrations likely reflect cardiac strain in the context of diagnoses such as ACS (10 ) , PE (26 ) , COPD (27 ) , pneumonia (28 ) , and sepsis (6 ) . The novel interleukin receptor family member sST2 was associated with powerful prognostic value out to 4 years from presentation with acute dyspnea. Although ST2 is expressed on type-2 T helper cells and has a phylogenetic background in the inflammatory system (29 ) , it has a well-characterized, perhaps primary role in mediating fibroproliferative activity in the heart (30, 31 ) , and thus functions in a pivotal step in cardiac remodeling. Indeed, the ST2 gene is markedly upregulated in cardiac myocytes and fibroblasts subjected to mechanical strain (32 ) and plays a pivotal role in the cardiac response to pressure and volume overload, possibly through reduction in myocyte apoptosis. In animal models, interruption of normal ST2 signaling or infusion of large amounts of sST2 results in unchecked myocardial fibrosis, hypertrophy, ventricular remodeling, and death (30, 31 ) . Such findings correlate quite closely with what is observed in ADHF patients with high levels of sST2. In addition, sST2 values are prognostic in pulmonary diseases (33 ) ; ST2 may also be pivotal in the development of acute lung injury during systemic sepsis (34 ) . In acutely dyspneic patients sST2 concentrations are strongly predictive of mortality even in the context of low NT-proBNP levels, confirming the importance of sST2 in patients without HF (33, 35 ) . Although inflammation is a prognostically meaningful process in acute illness, it is of note that despite the association of CRP and eotaxin to adverse cardiovascular outcomes, neither had prognostic value in the context of sST2 results (22, 36 ) . The superiority of sST2 over CRP or eotaxin might be attributable to its incremental prognostic value as reflected in the intersection between inflammation and cardiovascular stress predicted by sST2.
We found lower hemoglobin concentrations to be independently associated with worse outcomes. This result is consistent with other studies that have demonstrated that anemia is prognostic for mortality in various patient populations suffering from HF as well as other diseases (37, 38 ) . Although impairment in renal function, highly prevalent in patients with acute dyspnea and ADHF, may partially explain lower hemoglobin (and attendant risk), it is well recognized that derangement in hematologic indices can occur by mechanisms beyond renal dysfunction. The relevant challenge is to ascertain the mechanism for anemia and potential modes for addressing the risk associated with Biomarkers and Long-Term Outcomes in Dyspnea low hemoglobin. Indeed, therapies now exist for treating low hemoglobin, but speculation remains as to whether their selective application in the highest risk patients would be associated with improved outcomes.
Because it may be challenging to establish prognosis in patients with acute dyspnea, our data provide potentially useful information to the clinician for ascertaining short-term and long-term prognosis in this group of patients. The risk prediction model that we assembled performed well both in the derivation cohort as well as in an external validation cohort, which underlines its significance and suggests portability. This method for risk prediction may therefore be useful in clinical trials as well as everyday clinical use. Although there was undoubtedly some optimism present regarding the PRIDE results, given the modeling strategy, the overall good discrimination demonstrated in the external validation cohort suggests that the our risk model is fairly robust. Although there were significant differences in the HRs between derivation and validation cohorts, this result is more reflective of the absolute event rates in the referent groups; in PRIDE it was quite low, whereas in the Linz cohort it was quite high. Thus, the results of our analysis provide additional reassurance, because they imply that the risk prediction model is useful, independent of baseline risk.
A limitation of our study was that we determined biomarker results only for measurements at the time of patient presentation, and we were not able to evaluate the risk of mortality with respect to serial measurements of biomarkers, as has been described with several biomarkers. Furthermore, given the large number of variables examined for inclusion in the model, overestimation of risk coefficients may have occurred. The validation of the model in a separate cohort of dyspneic patients provided reassurance that this model is robust and generalizable.
We have shown that with the use of clinical and biochemical variables, patients at lower vs higher short-term, intermediate, and longer-term risk may be identified with relative ease. Although adding extra biomarkers to the conventional ones currently in use (such as natriuretic peptides) may increase the cost, the enhanced knowledge regarding risk may be incrementally useful for triaging as well as for therapeutic decision-making. In light of emerging data regarding targeted therapy to decrease concentrations of specific biomarkers (such as NT-proBNP), a robust multimarker panel-if therapeutic implications were similarly associated with each biomarker employed-would have both prognostic and therapeutic implications. Further study to validate such an approach is warranted. 
